Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labò G
Int J Tissue React. 1983;5(4):339-43.
Ten patients with Zollinger-Ellison syndrome (4 with intact stomach and 6 with previous partial gastrectomy) received ranitidine (600-1200 mg daily) for 2-24 months (mean 14 months). The inhibitory effect of ranitidine on acid secretion was evaluated by measuring acid output during the third hour following a single drug administration in all cases, and by the 24-hour intragastric pH profile in 5 patients. Therapeutic efficacy was assessed by clinical and endoscopic criteria. Ranitidine at different dosages, related to the rate of acid secretion, was effective in controlling peptic disease and diarrhoea in the majority of patients. The secretory parameters used in this study allowed evaluation of the inhibitory effect of ranitidine on acid secretion, in order to select the best therapeutic dose and to decide on surgical cure in the patients non-responsive even to the highest dosage.
10例卓-艾综合征患者(4例胃完整,6例曾行部分胃切除术)接受雷尼替丁治疗(每日600 - 1200毫克),疗程2 - 24个月(平均14个月)。在所有病例中,通过单次给药后第3小时测量胃酸分泌量来评估雷尼替丁对胃酸分泌的抑制作用,5例患者则通过24小时胃内pH值曲线进行评估。通过临床和内镜标准评估治疗效果。与胃酸分泌速率相关的不同剂量雷尼替丁对大多数患者控制消化性疾病和腹泻有效。本研究中使用的分泌参数有助于评估雷尼替丁对胃酸分泌的抑制作用,以便选择最佳治疗剂量,并对即使使用最高剂量仍无反应的患者决定是否进行手术治疗。